22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for biotechs...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

1Q approvals

1Q approvals CompanyApprovalAlexion Pharmaceuticals Inc. (NASDAQ:ALXN)Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D)Amgen Inc. (NASDAQ:AMGN)Japan approves Repatha evolocumab to treat familial hypercholesterolemia or hypercholesterolemia in patients at high risk of cardiovascular events...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

OBI-822/821: Phase II/III data

Top-line data from a double-blind, international Phase II/III trial in 349 treatment-experienced patients with histologically or cytologically confirmed metastatic breast cancer showed that OBI-822/821 plus low-dose cyclophosphamide missed the primary endpoint of improving PFS vs....
02:39 , Feb 23, 2016 |  BC Extra  |  Clinical News

OBI breast cancer therapy misses Phase II/III endpoint

OBI Pharma Inc. (TPEx:4174) said OBI-822/821 missed the primary endpoint of progression free survival (PFS) in a top-line analysis of its Phase II/III study to treat metastatic breast cancer. The company said the data showed...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

Taiwan's post-bubble prognosis

More than a year after BioCentury chronicled investor enthusiasm for biotechs in Taiwan, the bubble has deflated. It's tempting to blame the downturn simply on retail investors who didn't get up to speed as quickly...
07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc.'s BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its rationale...
07:00 , Oct 15, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved in...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Optimer Pharmaceuticals Inc. Inc. cancer news

Optimer plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to treat metastatic...
00:38 , Oct 9, 2012 |  BC Extra  |  Company News

Optimer selling stake in Taiwan subsidiary for $60M

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to...